Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis.
Saved in:
| Title: | Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis. |
|---|---|
| Authors: | Mansell, Kerry1 (AUTHOR) kerry.mansell@usask.ca, Bhimji, Hishaam1 (AUTHOR), Eurich, Dean2 (AUTHOR), Mansell, Holly1 (AUTHOR) |
| Source: | BMC Health Services Research. 11/12/2019, Vol. 19 Issue 1, p1-8. 8p. 2 Charts, 2 Graphs. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 14726963 |
|---|---|
| DOI: | 10.1186/s12913-019-4680-2 |
